Xbrane Biopharma Q3 loss narrows 51% to SEK 11.7 million; Q3 revenue rises to SEK 54.8 million

Bitget2026/10/30 07:38

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xbrane Biopharma’s third-quarter 2026 loss narrowed 51% year over year to SEK 11.7 million.
Revenue rose to SEK 54.8 million, including SEK 54.6 million from Ximluci product sales.
Quarter-end cash and cash equivalents fell 60% year over year to SEK 37.4 million.
The ranibizumab biosimilar candidate received FDA approval on October 27; partners will work toward a rapid US launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xbrane Biopharma AB published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xbrane Biopharma Q3 loss narrows 51% to SEK 11.7 million; Q3 revenue rises to SEK 54.8 million

You may also like

Crypto prices